CYP1A1*2B (Val) allele is overrepresented in a subgroup of acute myeloid leukemia patients with poor-risk karyotype associated with NRAS mutation, but not associated with FLT3 internal tandem duplication

Blood

Volumn 101, Issue 7, 2003, Pages 2770-2774

  Bowen, David T ^a   Frew, Marion E ^b   Rollinson, Sara ^b   Roddam, Philippa L ^b   Dring, Ann ^b   Smith, Martyn T ^b   Langabeer, Stephen E ^b   Morgan, Gareth J ^b  

^a NINEWELLS HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CD135 ANTIGEN; CYTOCHROME P450 1A1; FLT3 PROTEIN, HUMAN; HRAS PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN P21; PROTEIN TYROSINE KINASE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLELE; ARTICLE; CHROMOSOME DELETION; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CYTOGENETICS; DISEASE ASSOCIATION; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; GENETIC CODE; GENETIC RISK; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; ONCOGENE RAS; PRIORITY JOURNAL; TANDEM REPEAT; ACUTE DISEASE; ADOLESCENT; GENETICS; KARYOTYPING; MIDDLE AGED; MUTATION; MYELOID LEUKEMIA; PROGNOSIS;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ALLELES; CYTOCHROME P-450 CYP1A1; FMS-LIKE TYROSINE KINASE 3; GENE FREQUENCY; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID; MIDDLE AGED; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR PROTEIN-TYROSINE KINASES; TANDEM REPEAT SEQUENCES;

EID: 0038446667     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-01-0228     Document Type: Article

References (34)

1. Pedersen-Bjergaard J, Andersen MK, Christiansen DH, Nerlov C. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood. 2002;99:1909-1912.
2. Taylor JA, Sandler DP, Bloomfield CD, et al. Ras oncogene activation and occupational exposures in acute myeloid leukemia. J Natl Cancer Inst, 1992;84:1626-1632.
3. Crane MM, Keating MJ. Exposure histories in acute nonlymphocytic leukemia patients with a prior preleukemic condition. Cancer. 1991;67:2211-2214.
4. Larson RA, Wang Y, Banerjee M, et al. Prevalence of the inactivating 609C - T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood. 1999;94:803-807.
5. Allan JM, Wild CP, Rollinson S, et al. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc Natl Acad Sci U S A. 2001;11592-11597.
6. Smith MT, Wang Y, Kane E, et al. Low NAD(P)H: quinone oxidoreductase 1 activity is associated with increased risk of acute leukemia in adults. Blood. 2001;97:1422-1426.
7. Rollinson S, Roddam P, Kane E, et al. Polymorphic variation within the glutathione S-transferase genes and risk of adult acute leukaemia. Carcinogenesis. 2000;21:43-47.
8. Roddam PL, Rollinson S, Kane E, et al. Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia. Pharmacogenetics, 2000;10:605-615.
9. Gustincich S, Manfioletti G, Del Sal G, Schneider C, Carninci P. A fast method for high-quality genomic DNA extraction from whole human blood. Biotechniques. 1991;11:298-300, 302.
10. Mitelman F. ISCN: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger; 1995.
11. Moorman AV, Roman E, Willett EV, et al. Karyotype and age in acute myeloid leukemia: are they linked? Cancer Genet Cytogenet. 2001;126:155-161.
12. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukemia Working Parties. Blood. 1998;92:2322-2333.
13. Yokota S, Kiyoi H, Nakao M, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies: a study on a large series of patients and cell lines. Leukemia. 1997;11:1605-1609.
14. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98:1752-1759.
15. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977;74:5463-5467.
16. Horiike S, Misawa S, Nakai H, et al. N-ras mutation and karyotypic evolution are closely associated with leukemic transformation in myelodysplastic syndrome. Leukemia. 1994;8:1331-1336.
17. Bashey A, Gill R, Levi S, et al. Mutational activation of the N-ras oncogene assessed in primary clonogenic culture of acute myeloid leukemia (AML): implications for the role of N-ras mutation in AML pathogenesis. Blood. 1992;79:981-989.
18. Kiyol H, Naoe T, Nakano Y, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 1999;93:3074-3080.
19. Whitlock JP Jr. Induction of cytochrome P4501A1. Annu Rev Pharmacol Toxicol. 1999;39:103-125.
20. Wormhoudt LW, Commandeur JN, Vermeulen NP. Genetic polymorphisms of human N-acetyl-transferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity. Crit Rev Toxicol. 1999;29:59-124.
21. Kiyohara C, Hirohata T, Inutsuka S. The relationship between aryl hydrocarbon hydroxylase and polymorphisms of the CYP1A1 gene. Jpn J Cancer Res. 1996;87:18-24.
22. Crofts F, Taioli E, Trachman J, et al. Functional significance of different human CYP1A1 genotypes. Carcinogenesis. 1994;15:2961-2963.
23. Song N, Tan W, Xing D, Lin D. CYP 1A1 polymorphism and risk of lung cancer in relation to tobacco smoking: a case-control study in China. Carcinogenesis. 2001;22:11-16.
24. Ishibe N, Hankinson SE, Colditz GA, et al. Cigarette smoking, cytochrome P450 1A1 polymorphisms, and breast cancer risk in the Nurses' Health Study. Cancer Res. 1998;58:667-671.
25. Kiss I, Sandor J, Pajkos G, et al. Colorectal cancer risk in relation to genetic polymorphism of cytochrome P450 1A1, 2E1, and glutathione-S-transferase M1 enzymes. Anticancer Res. 2000;20:519-522.
26. Bertazzi PA, Consonni D, Bachetti S, et al. Health effects of dioxin exposure: a 20-year mortality study. Am J Epidemiol. 2001;153:1031-1044.
27. Kane EV, Roman E, Cartwright R, Parker J, Morgan G. Tobacco and the risk of acute leukaemia in adults. Br J Cancer. 1999;81:1228-1233.
28. Bjork J, Albin M, Mauritzson N, et al. Smoking and acute myeloid leukemia: associations with morphology and karyotypic patterns and evaluation of dose-response relations. Leuk Res. 2001;25:865-872.
29. Parry TE. The non-random distribution of point mutations in leukaemia and myelodysplasia: a possible pointer to their aetiology. Leuk Res. 1997;21:559-574.
30. Hernandez-Boussard TM, Hainaut P. A specific spectrum of p53 mutations in lung cancer from smokers: review of mutations compiled in the IARC p53 database. Environ Health Perspect. 1998;106:385-391.
31. Kawajiri K, Eguchi H, Nakachi K, Sekiya T, Yamamoto M. Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. Cancer Res. 1996;56:72-76.
32. Nebert DW, Roe AL, Dieter MZ, et al. Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and apoptosis. Biochem Pharmacol. 2000;59:65-85.
33. Park JY, Shigenaga MK, Ames BN. Induction of cytochrome P4501 A1 by 2,3,7,8-tetrachlorodibenzo-p-dioxin or indolo(3,2-b)carbazole is associated with oxidative DNA damage. Proc Natl Acad Sci U S A. 1996;93:2322-2327.
34. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodyspiasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol. 2001;19:1405-1413.